Belite Bio, Inc. ADR (BLTE) has released an update.
Belite Bio, Inc has announced the submission of Tinlarebant, a novel oral treatment for Stargardt Disease (STGD1) and Dry AMD, for clinical trials in Japan, following positive findings from a 24-month Phase 2 trial. The company is also progressing with a global Phase 3 trial, with interim data anticipated in the fourth quarter of 2024. Tinlarebant aims to reduce the progression of these retinal diseases by decreasing the accumulation of retinal toxins.
For further insights into BLTE stock, check out TipRanks’ Stock Analysis page.
